MedPath
NMPA Approval

Raltegravir Potassium for oral suspension

H20180006

April 12, 2018

Drug Information

拉替拉韦钾干混悬剂

艾生特

口服混悬剂

100mg(按拉替拉韦计)

化学药品

April 12, 2018

April 11, 2023

Company Information

Applicant Company

1 Merck Drive, P.O.Box 100, Whitehouse Station, NJ 08889 United States of America

Manufacturing Company

2110 East Galbraith Road, Cincinnati, OH 45237 United States of America

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

拉替拉韦钾干混悬剂 - NMPA 批准文号 | MedPath